Literature DB >> 21515290

The effect of metoprolol alone and combined metoprolol-felodipin on the digital microcirculation of patients with primary Raynaud's syndrome.

Zoltan Csiki1, Ildiko Garai, Amir H Shemirani, Gabor Papp, Katalin S Zsori, Csilla Andras, Margit Zeher.   

Abstract

OBJECTIVES: Calcium channel inhibitors have beneficial impact on microcirculation, but beta-blocker effect is controversial. Clinicians still do not agree on beta-blocker combination with other treatments in the management of impaired microcirculation. The aim of the present study was to describe the effects of beta-blocker metoprolol monotherapy and combined with calcium channel inhibitor felodipin on digital microcirculation in primary Raynaud's syndrome.
METHODS: We enrolled in this study 46 patients suffering from both hypertension and primary Raynaud's syndrome. Fifteen patients were treated with beta-blocker monotherapy (metoprolol), 13 received combined beta-blocker and calcium channel blocker therapy (felodipin and metoprolol), while 18 patients without any medications served as controls. Measurement of digital microcirculation was carried out with laser Doppler scanner. RESULTS AND
CONCLUSIONS: Our investigation concludes that the concurrent administration of beta-blockers with calcium channel inhibitors positively reduces symptoms in patients suffering from Raynaud's syndrome.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21515290     DOI: 10.1016/j.mvr.2011.04.004

Source DB:  PubMed          Journal:  Microvasc Res        ISSN: 0026-2862            Impact factor:   3.514


  8 in total

1.  Comparison of non-invasive assessment of arrhythmias, conduction disturbances and cardiac autonomic tone in systemic sclerosis and systemic lupus erythematosus.

Authors:  Piotr Bienias; Michał Ciurzyński; Bartłomiej Kisiel; Anna Chrzanowska; Katarzyna Ciesielska; Maria Siwicka; Agnieszka Kalińska-Bienias; Marek Saracyn; Monika Lisicka; Joanna Radochońska; Piotr Pruszczyk
Journal:  Rheumatol Int       Date:  2018-11-12       Impact factor: 2.631

Review 2.  Primary heart involvement in systemic sclerosis, from conventional to innovative targeted therapeutic strategies.

Authors:  Arianna Ferlito; Corrado Campochiaro; Alessandro Tomelleri; Lorenzo Dagna; Giacomo De Luca
Journal:  J Scleroderma Relat Disord       Date:  2022-03-24

Review 3.  Cardiac arrhythmias and conduction defects in systemic sclerosis.

Authors:  Alessandra Vacca; Christophe Meune; Jessica Gordon; Lorinda Chung; Susanna Proudman; Shervin Assassi; Mandana Nikpour; Tatiana S Rodriguez-Reyna; Dinesh Khanna; Robert Lafyatis; Marco Matucci-Cerinic; Oliver Distler; Yannick Allanore
Journal:  Rheumatology (Oxford)       Date:  2013-11-15       Impact factor: 7.580

Review 4.  Oral vasodilators for primary Raynaud's phenomenon.

Authors:  Marlene Stewart; Joanne R Morling
Journal:  Cochrane Database Syst Rev       Date:  2012-07-11

Review 5.  Calcium channel blockers for primary Raynaud's phenomenon.

Authors:  Holly Ennis; Michael Hughes; Marina E Anderson; Jack Wilkinson; Ariane L Herrick
Journal:  Cochrane Database Syst Rev       Date:  2016-02-25

Review 6.  Raynaud's Phenomenon: A Brief Review of the Underlying Mechanisms.

Authors:  Manal M Fardoun; Joseph Nassif; Khodr Issa; Elias Baydoun; Ali H Eid
Journal:  Front Pharmacol       Date:  2016-11-16       Impact factor: 5.810

7.  Acute Heart Failure in Scleroderma Renal Crisis: A Case Study for Review of Cardiac Disease in Systemic Sclerosis.

Authors:  Abhimanyu Amarnani; Perry Wengrofsky; Cindy L Tsui; Pramod Theetha Kariyanna; Naureen Kabani; Louis Salciccioli; Isabel M McFarlane
Journal:  Am J Med Case Rep       Date:  2019-11-05

8.  Electrocardiographic markers for the prediction of ventricular arrhythmias in patients with systemic sclerosis.

Authors:  Veronika Sebestyén; Gabriella Szűcs; Dénes Páll; Dóra Ujvárosy; Tamás Ötvös; Imre Csige; Tamás Pataki; István Lőrincz; Zoltán Szabó
Journal:  Rheumatology (Oxford)       Date:  2020-03-01       Impact factor: 7.580

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.